Is this device really worth the price tag?

Delhi Capitals will hope their misfiring top order finally fires as they chase their third straight win of IPL 2026 against a ...

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

Lifestyle choices may be overlooked, but they play a crucial role in determining your eye health. Here are four factors you ...

Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...

Unbeaten in two games, Delhi Capitals look to continue winning momentum at home today against winless GT, who will see ...

Delhi Capitals are off to a strong start with two wins, showcasing a balanced bowling attack and eager to extend their ...

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

While the Capitals have won both their matches so far against Lucknow Super Giants and Mumbai Indians, the Titans lost to ...